Five things to watch in US Supreme Court oral argument in Amgen v Sanofi
Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.